Patents/Inventors

Christopher G. Nasveschuk

Stoneham, MAUS23 patents

23 Patents

US126054502026
C3-carbon Linked Glutarimide Degronimers for Target Protein Degradation
C4 THERAPEUTICS, Inc.
0 cites
US125706262026
Degraders and Degrons for Targeted Protein Degradation
C4 Therapeutics, Inc.
0 cites
US125594922026
BRAF Degraders
C4 Therapeutics, Inc.
0 cites
US125287972026
Heterocyclic Compounds for Medical Treatment
C4 Therapeutics, Inc.
0 cites
US124862902025
Isoindolinone and Indazole Compounds for the Degradation of EGFR
C4 THERAPEUTICS, Inc.
0 cites
US124862532025
Therapeutics for the Degradation of Mutant BRAF
C4 THERAPEUTICS, Inc.
0 cites
US124545212025
Targeted Protein Degradation
C4 Therapeutics, Inc.
0 cites
US124417402025
N/o-linked Degrons and Degronimers for Protein Degradation
C4 THERAPEUTICS, Inc.
0 cites
US124212202025
Bicyclic-substituted Glutarimide Cereblon Binders
C4 THERAPEUTICS, Inc.
0 cites
US123714422025
Isoindolinone and Indazole Compounds for the Degradation of EGFR
C4 Therapeutics, Inc.
0 cites
US122275042025
Spirocyclic Compounds
C4 Therepeutics, Inc.
0 cites
US121802252024
N/o-linked Degrons and Degronimers for Protein Degradation
C4 Therapeutics, Inc.
0 cites
US121577352024
Compounds for Targeted Degradation of BRD9
C4 Therapeutics, Inc.
0 cites
US120764052024
Heterocyclic Degronimers for Target Protein Degradation
C4 Therapeutics, Inc.
0 cites
US120487472024
Substituted Piperidine Degronimers for Target Protein Degradation
C4 Therapeutics, Inc.
0 cites
US120487482024
Spirocyclic Degronimers for Target Protein Degradation
C4 Therapeutics, Inc.
0 cites
US120494642024
Compounds for Targeted Degradation of BRD9
C4 Therapeutics, Inc.
0 cites
US119925312024
C 3 -carbon Linked Glutarimide Degronimers for Target Protein Degradation
C4 Therapeutics, Inc.
0 cites
US117533972023
Cereblon Binders for the Degradation of Ikaros
C4 Therapeutics, Inc.
0 cites
US116919722023
Compounds for Targeted Degradation of BRD9
C4 Therapeutics, Inc.
0 cites
US116739022023
Isoindolinone and Indazole Compounds for the Degradation of EGFR
C4 Therapeutics, Inc.
0 cites
US116239292023
Spirocyclic Compounds
C4 Therapeutics, Inc.
0 cites
US115847482023
Spirocyclic Compounds
C4 Therapeutics, Inc.
0 cites